P1 trials exist to determine safety and tolerability. By definition, a P1 dose expansion study will dose patients at the optimal P2 levels to establish efficacy.
If that efficacy doesn't exist, there's little point running a P2.
IMU have already stated they are expanding the trial to focus on the 1 CR. This likely means they won't waste the capital on pursuing P2 solid tumours outside of gastrointestinal cancers.
IMU Price at posting:
4.4¢ Sentiment: Sell Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)